Abstract: A method of treatment of a neurodegenerative disease which is associated with a decline in mitochondrial activity, includes administering to a person in need of such treatment at least one of Glycolic acid or a pharmaceutically acceptable salt or ester thereof, and D-lactic acid or a pharmaceutically acceptable salt or ester thereof.

Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

Abstract: The invention comprises a fault-tolerant clock synchronization method with high precision, hardware implementations thereof and the corresponding digital circuits, designed to contain metastability.

Abstract: A long-term stable photoactive composition, namely a phosphorescent composition or a TTA-photon upconversion composition, contains: a) at least one compound, which has a triplet state capable of energy transfer via an emissive process or a non-emissive process, wherein the at least one compound having a triplet state is i) at least one phosphorescent compound and/or ii) at least one sensitizer compound being capable of absorbing radiation at a first frequency v1 and at least one emissive compound, wherein the at least one sensitizer compound is capable of transferring energy to the at least one emissive compound and wherein the at least one emissive compound, after obtaining energy transferred from the at least one sensitizer compound, is capable of emitting light at a second frequency v2, wherein the following equation is fulfilled: v2>v1, wherein the at least one sensitizer compound is capable of a triplet-triplet energy transfer to the at least one emissive compound and wherein the at least one emissi

Abstract: The invention comprises a learned model of human body shape and pose dependent shape variation that is more accurate than previous models and is compatible with existing graphics pipelines. Our Skinned Multi-Person Linear model (SMPL) is a skinned vertex based model that accurately represents a wide variety of body shapes in natural human poses. The parameters of the model are learned from data including the rest pose template, blend weights, pose-dependent blend shapes, identity-dependent blend shapes, and a regressor from vertices to joint locations. Unlike previous models, the pose-dependent blend shapes are a linear function of the elements of the pose rotation matrices. This simple formulation enables training the entire model from a relatively large number of aligned 3D meshes of different people in different poses. The invention quantitatively evaluates variants of SMPL using linear or dual-quaternion blend skinning and show that both are more accurate than a Blend SCAPE model trained on the same data.

Abstract: A training apparatus includes adjustable resistance means; means for continuously determining an actual configuration of the training apparatus during exercise; means for generating a control signal for an audio device, the control signal being at least partially based on the actual configuration of the training apparatus; and means for outputting the control signal.

Abstract: The present invention belongs to the field of biotechnology. More specifically, the present invention provides a protease, a non-naturally occurring fusion protein comprising a corresponding protease recognition site, expression vectors encoding same, host cells comprising said expression vectors, kit of parts as well as methods applying the protease, fusion protein, and uses thereof, as defined in the claims. The presently disclosed protease/protease recognition site is particularly useful in methods requiring an orthogonal set of proteases, and is suitable for use in both prokaryotic and selected eukaryotic expression systems.

Abstract: The present invention relates to methods of identifying substances that modulate GA action through targeting its receptor or acting as a GA functional analog, sensor peptides especially designed for that methods as well as a strain of the species Saccharomyces cerevisiae expressing such a sensor peptide.

Abstract: The present invention relates to a method for the in vitro detection of a latent tuberculosis infection (LTBI) in a subject, wherein said method comprises determining at least one nucleotide sequence and/or at least one polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population of said subject, and wherein the presence of said at least one nucleotide sequence and/or said at least one polypeptide is indicative for said latent tuberculosis infection. In particular, the blood cell population is enriched for hematopoietic stem cells. The invention also relates to a pharmaceutical composition for use in the treatment of the LTBI in the subject, wherein it is determined if the nucleotide sequence and/or the polypeptide of Mtb is/are present in the blood cell population. Further, the invention relates to kits for carrying out the methods of the invention. The invention also relates to the use of the kits.

Abstract: The present invention relates to a method for determining in an expedient manner and with minimal sample consumption the structure of an unknown carbohydrate by using ion mobility-mass spectrometry (IM-MS) in negative ionization mode and fragmentation and a database containing structures of carbohydrates and/or of the fragments of the negative ions of carbohydrates, and for each of the structures of the target carbohydrates the collision cross section value and the mass-to-charge ratio value of the negative ion thereof, and for each of the structures of the fragments of the negative ions of the target carbohydrates the collision cross section value and the mass-to-charge ratio value of the fragment of the negative ion of the target carbohydrate.

Abstract: A method of treating a human patient with depressive and/or anxiety symptoms which includes administering an effective amount of a V1B receptor antagonist and/or CRHR1 antagonist to the patient in need thereof, wherein the patient's genome has certain polymorphoric variants.

Abstract: The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.

Abstract: The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them.

Abstract: A method for forecasting an environmental event/a type of environmental event includes acquiring at least one test data set of at least one behavioral and/or physiological parameter of a population of animals; generating a test profile based on said at least one test data set, representing behavior and/or physiological status of the population of animals; calculating a ratio between the test profile and a first reference profile; and setting an alert, if said ratio reaches a predefined threshold value.

Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.

Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.

Abstract: The present invention relates to a method for producing a panel of cells (i.e. a cell library) expressing various different mutant variants of a protein of interest, wherein only one of said mutant variants is expressed per cell from a single gene copy. The present invention also relates to a method or cell library for identifying a mutant variant of a protein of interest having a different or modified biological activity as compared to the corresponding wild-type protein of interest. According to the present invention the identified mutant variant of a protein of interest may be applied for white biotechnology.

Abstract: The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

Abstract: A solution for synchronizing a network comprising a plurality of interconnected nodes provides a stable synchronized state, especially for large scale networks. Signal transmission speed and the length of each interconnection of the network is configured to cause a delay of the signals received by a node from the other node of the interconnection which is larger than one millionth of the free-running period of the controllable oscillator of the receiving node such that Network-wide synchronization of oscillators is achieved for all nodes of the network in a continuous self-organized process in interaction with the other node of the network.

Abstract: The invention relates to the in vitro and in cellulo detection of the cofactors nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). Provided is a sensor molecule for fluorescence- or luminescence-based detection of a nicotinamide adenine dinucleotide analyte, in particular for detecting the concentrations of NAD+, NADP+ and/or the ratios of the concentrations of NAD+/NADH and NADP+/NADPH, the sensor comprising (i) a binding protein (BP) for the nicotinamide adenine dinucleotide analyte, the BP being derived from sepiapterin reductase (SPR; EC 1.1.1.153) (ii) an SPR ligand (SPR-L) capable of intramolecular binding to said BP in the presence of the oxidized form of said analyte; and (iii) at least one fluorophore.